Skip to main content
SpringerLink
Log in

Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials

  • Short Communication
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG PIO™ trial investigators (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16:147–158

    Article  CAS  PubMed  Google Scholar 

  2. Merker L, Häring HU, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC, EMPA-REG EXTEND™ MET investigators (2015) Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabet Med 32:1555–1567

    Article  CAS  PubMed  Google Scholar 

  3. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128

    Article  CAS  PubMed  Google Scholar 

  4. DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC (2015) Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabet esCare 38:384–393

    CAS  Google Scholar 

  5. Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC (2015) Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 3:394–402

    Article  Google Scholar 

Download references

Author’s contribution

Matteo Monami was involved in each of the following points: 1. design, 2. data collection, 3. analysis, 4. writing manuscript. Stefania Zannoni and Besmir Nreu were involved in each of the following points: 1. data collection, 2. manuscript revision. Edoardo Mannucci was involved in each of the following points: 1. design, 2. data collection, 3. analysis, 4. writing manuscript. All the authors approved the final version of this manuscript.

Author information

Authors and Affiliations

  1. Diabetology, Careggi Teaching Hospital, Via delle Oblate 4, 50141, Florence, Italy

    Matteo Monami, Stefania Zannoni & Edoardo Mannucci

  2. Geriatric Medicine, Careggi Teaching Hospital, Via delle Oblate 4, 50141, Florence, Italy

    Besmir Nreu

Authors
  1. Matteo Monami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefania Zannoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Besmir Nreu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Edoardo Mannucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matteo Monami.

Ethics declarations

Conflict of interest

Edoardo Mannucci has received consultancy fees from AstraZeneca, Boehringer, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda; speaking fees from AstraZeneca, Boehringer, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda; research grants from AstraZeneca, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Sanofi. Stefania Zannoni and Besmir Nreu have no conflicts of interest to declare. Matteo Monami has received speaking fees from BMS, Eli Lilly, Merck, Novo Nordisk, Sanofi Takeda, and consultancy fees from Boehringer.

Ethical standard

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Human and animal rights

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Informed consent

A formal informed consent was obtained for all participants.

Additional information

Managed by Massimo Federici.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Monami, M., Zannoni, S., Nreu, B. et al. Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetol 54, 411–413 (2017). https://doi.org/10.1007/s00592-016-0928-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-016-0928-z

Keywords

Search

Navigation